Table 3:
Other outcomes
|
Characteristic |
Hydromorphone (N=66) |
Morphine (N=68) |
P value* |
|---|---|---|---|
| In the first 24 hours | |||
| Opioid** | |||
| Any received | 47 (71) | 44 (65) | 0.463 |
| Amount received†, mg | 30.0 (7.5, 45.0) | 22.5 (15.0, 37.5) | 0.769 |
| Nausea | |||
| Self-report or treatmentⱡ | 30 (45) | 32 (47) | 0.864 |
| Treatment | 22 (33) | 22 (32) | >0.999 |
| Pruritus | |||
| Self-report or treatmentⱡ | 41 (62) | 41 (60) | 0.861 |
| Treatment | 7 (11) | 13 (19) | 0.226 |
| Sedation§ | 1 (2) | 3 (4) | 0.321 |
| Unsatisfied with analgesia | 5 (8) | 7 (10) | 0.764 |
| Hospital Length of Stay, days | 0.814 | ||
| 1 | 1 (2) | 1 (1) | |
| 2 | 23 (35) | 23 (34) | |
| 3 | 42 (64) | 43 (63) | |
| 4 | 0 (0) | 1 (1) |
All values reported as n(%) except as noted.
*
The amount of opioid received and hospital length of stay are compared between groups using the rank sum test. Other characteristics are compared between groups using Fisher’s exact test.
**
Does not include intraoperative fentanyl.
†
Only for those who received opioids are included (N=47 and N=44 for hydromorphone and morphine respectively), reported as median (25th, 75th). Reported in oral morphine milligram equivalents.
ⱡ
Defined as reporting symptoms as moderate or severe or receiving pharmacologic treatment for symptoms
§
Defined as any negative score on the Richmond Agitation Sedation Scale.